During the past decade, CISSSL - Hopital Pierre-Le Gardeur conducted 4 clinical trials. In the 10-year time frame, 4 clinical trials started and 3 clinical trials were completed, i.e. on average, 75% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 2 clinical trials were completed. i.e. 100% of trials that started reached the finish line.

Out of the total clinical trials conducted in "CISSSL - Hopital Pierre-Le Gardeur" #1 sponsor was "Axio Research. LLC" with 1 trials, followed by "Bayer" with 1 trials sponsored, "Bristol-Myers Squibb" with 1 trials sponsored, "Idorsia Pharmaceuticals Ltd." with 1 trials sponsored and "Milestone Pharmaceuticals Inc." with 1 trials sponsored. Other sponsors include -4 different institutions and companies that sponsored additional 6 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "CISSSL - Hopital Pierre-Le Gardeur" #1 collaborator was "National Heart, Lung, and Blood Institute (NHLBI)" with 2 trials as a collaborator, "Abbott" with 1 trials as a collaborator, "Albany Stratton VA Medical Center" with 1 trials as a collaborator, "Cedars-Sinai Medical Center" with 1 trials as a collaborator and "Columbia University" with 1 trials as a collaborator. Other collaborators include 8 different institutions and companies that were collaborators in the rest 18 trials.

According to Clinical.Site data, the most researched conditions in "CISSSL - Hopital Pierre-Le Gardeur" are "Cardiovascular Diseases" (2 trials), "Coronary Disease" (2 trials), "Heart Diseases" (2 trials), "Acute Myocardial Infarction" (1 trials) and "Atherosclerosis" (1 trials). Many other conditions were trialed in "CISSSL - Hopital Pierre-Le Gardeur" in a lesser frequency.

Most popular intervention types in "CISSSL - Hopital Pierre-Le Gardeur" are "Drug" (5 trials), "Behavioral" (1 trials), "Combination Product" (1 trials) and "Procedure" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (2 trials), "Apixaban" (1 trials), "Apixaban matching placebo" (1 trials), "Asundexian (BAY2433334)" (1 trials) and "Asundexian matching placebo" (1 trials). Other intervention names were less common.

The vast majority of trials in "CISSSL - Hopital Pierre-Le Gardeur" are 6 trials for "All" genders.

Currently, there are NaN active trials in "CISSSL - Hopital Pierre-Le Gardeur". undefined are not yet recruiting, 1 are recruiting, 1 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 1 completed trials in CISSSL - Hopital Pierre-Le Gardeur, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in CISSSL - Hopital Pierre-Le Gardeur, 0 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 4 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 1 trials that are defined as “Not Applicable".